Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports.

Clin Neuropharmacol

G. Fontana Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Internal Medicine, Cardioangiology and Hepatology, Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Published: July 2005

Gamma-hydroxybutyric acid (GHB) is currently used to induce and maintain abstinence from alcohol. Cases of craving and desire to increase doses of GHB have been reported in both clinical trials and nonclinical self-administration. The enhancement of dopamine activity induced by GHB receptor activation might play a role in the euphoric effect and potential craving and the consequent abuse of this drug. Naltrexone (NTX), a mu-opioid antagonist, is effective in inducing and maintaining abstinence from alcohol, reducing relapses in heavy drinking and craving for alcohol in alcohol-dependent outpatients. Taking into account the alcohol antireward property of NTX, we tested its activity in reducing craving for GHB in 3 consecutive cases of alcoholics who manifested craving for this drug. In all patients the combination with NTX suppressed the craving for GHB. The antireward effect of NTX likely results from its interference with the GHB-induced dopamine release, leading to a partial blockade of the GHB reinforcing effect responsible of the craving for the drug. A combined therapy with GHB and NTX seems to be able to suppress craving for the former, thus improving the manageability and safety of treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.wnf.0000159954.49393.76DOI Listing

Publication Analysis

Top Keywords

gamma-hydroxybutyric acid
8
abstinence alcohol
8
craving
8
craving ghb
8
craving drug
8
ghb
7
ntx
5
suppression craving
4
craving gamma-hydroxybutyric
4
acid naltrexone
4

Similar Publications

The problem of finding a suitable biomarker to widen the detection window of γ-hydroxybutyric acid (GHB) intake remains a challenge in forensic toxicology. Based on previously published results, the present study deals with the evaluation of a fatty acid ester of GHB (4-palmitoyloxy butyrate (GHB-Pal)) in whole blood as a potential biomarker to extend the detection window of GHB use e.g.

View Article and Find Full Text PDF

Objective: To investigate the haemodynamic effects of gamma-hydroxybutyric acid (GHB) in isoflurane-anaesthetized pigs.

Study Design: Experimental, randomized, nonblinded, crossover study.

Animals: A group of six stress-resistant Landrace pigs (approximately 3 months old; three male, three female; bodyweight 39.

View Article and Find Full Text PDF

Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals disease severity biomarkers.

Metabolomics

December 2024

Division of Systems Biology, National Center for Toxicological Research, United States Food and Drug Administration, 3900 NCTR Road, Jefferson, AR, 72079, USA.

Introduction: Coronavirus disease 2019 (COVID-19) has widely varying clinical severity. Currently, no single marker or panel of markers is considered standard of care for prediction of COVID-19 disease progression. The goal of this study is to gain mechanistic insights at the molecular level and to discover predictive biomarkers of severity of infection and outcomes among COVID-19 patients.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to develop a method for detecting γ-hydroxybutyric acid (GHB) in human blood, urine, and oral fluid while accounting for its naturally occurring presence and potential in vitro production after sampling.
  • Researchers validated an LC-MS/MS method with a low limit of quantification (0.005 µg/mL in blood and 0.010 µg/mL in urine/oral fluid), achieving high extraction recovery rates and minimal bias.
  • Stability tests showed that GHB concentrations change over time in different blood preservatives, indicating that current detection cut-off levels for GHB might need to be adjusted, especially for samples stored at -20°C.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to investigate lung tissue changes in rats after administering baclofen, focusing on the expression of genes related to apoptosis (Bax and Bcl-2) in different lung cell types.
  • Twenty Wistar rats were divided into four groups, with varying observation times after receiving baclofen, to assess the corresponding histological and gene expression effects.
  • Results showed significant lung damage, including vascular issues and emphysema, peaking at 24 hours, with varying levels of Bax and Bcl-2 expression that indicated a dynamic response to baclofen administration.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!